Drug intelligence / Profile preview

XPC-391

Development stage: Discontinued
Lead developer: Neurocrine Biosciences
Modality: Small Molecules

Overview

XPC-391 is a **small molecule drug** developed by Xenon Pharmaceuticals for the treatment of nervous system diseases, with a primary indication in **epilepsy**. Development of XPC-391 reached the **preclinical stage** before it was discontinued. The specific mechanism of action, molecular target, and other pharmacological details have not been disclosed in publicly available sources.

Targets

SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN8A (NaV1.6)

Beyond the preview

Go deeper on XPC-391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XPC-391.

Explore the full profile